← Back to Search

Natural Killer Cell Therapy

SNK01 for Cancer

Phase 1
Waitlist Available
Research Sponsored by NKGen Biotech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights

Study Summary

This trial is testing a new cancer treatment made from a patient's own immune cells. It is for patients with advanced cancer who have not responded to other treatments.

Eligible Conditions
  • Solid Tumors
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the safety profile
Secondary outcome measures
To assess clinical objective response rate (ORR) of SNK01 in combination with avelumab in patients with refractory cancer
To assess clinical objective response rate (ORR) of SNK01 in combination with pembrolizumab in patients with refractory cancer
To assess clinical objective response rate (ORR) of SNK01 in patients with refractory cancer

Trial Design

5Treatment groups
Experimental Treatment
Group I: Cohort 4 - SNK01 with pembrolizumabExperimental Treatment2 Interventions
SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.
Group II: Cohort 4 - SNK01 with avelumabExperimental Treatment2 Interventions
SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.
Group III: Cohort 3 - High dose SNK01Experimental Treatment1 Intervention
SNK01 (high dose) administered once a week for five weeks.
Group IV: Cohort 2 - Medium dose SNK01Experimental Treatment1 Intervention
SNK01 (medium dose) administered once a week for five weeks.
Group V: Cohort 1 - Low dose SNK01Experimental Treatment1 Intervention
SNK01 (low dose) administered once a week for five weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SNK01
2019
Completed Phase 1
~30
Avelumab
2018
Completed Phase 2
~2450
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

NKGen Biotech, Inc.Lead Sponsor
6 Previous Clinical Trials
72 Total Patients Enrolled
Steven S. Cha, MDStudy DirectorNKGen Biotech, Inc.
1 Previous Clinical Trials
11 Total Patients Enrolled
Paul Chang, MPHStudy DirectorNKGen Biotech, Inc.
1 Previous Clinical Trials
11 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy
2019. "Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03941262.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top